Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nanjing Medical Focuses On Medical Trust

This article was originally published in PharmAsia News

Executive Summary

Nanjing Medical Co. Ltd. (NMC) and Nanjing Medical Group have transferred 66 percent of their combined share in NMC Baixin Pharmacy Co., Ltd. to subsidiary Nanjing Pharmaceutical Co., Ltd. The move seeks to consolidate resources for an integrated procurement and supply chain, enabling Nanjing Medical to maximize its business network and increase sales. NMC is also selling out its 30 percent share in Nanjing MeiRui Pharma Co. Ltd. to the latter's U.S. parent company Cal-Nan Horizon Quest, Inc. Analysts believe the divestment allows NMC to focus on its core business of medical trust. The company aims to increase its trust business from the current 500 million yuan to 1 billion yuan in 2008. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel